Few MS Patients Fail to Receive Disease-Modifying Therapy

A survey of neurologists showed that most patients with MS received DMT; that patient satisfaction and adherence were best with fingolimod; but that insurance coverage for fingolimod was worse than for self-injectable DMTs

According to a survey of neurologists published online April 3 in Patient Preference and Adherence, the vast majority of patients with multiple sclerosis received...

Clinical Research

MS Research Roundup: April 30, 2014

Cannabis for MS; Relapsing After Pregnancy; MS Interactive Map With Treatment Trends

Items of interest to multiple sclerosis researchers from around the Web...

Clinical Research, People

Editors' Pick

Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D

Neurology. 2014 Apr 29; 82(17):1556-63. PMID: 24778283. Abstract

Editors' Pick

Imaging outcomes for trials of remyelination in multiple sclerosis.

Mallik S, Samson RS, Wheeler-Kingshott C A, Miller DH

J Neurol Neurosurg Psychiatry. 2014 Apr 25. PMID: 24769473. Abstract

Race to Erase MS Forum and Expo

3 May 2014

Hyatt Regency Century Plaza in Los Angeles

Editors' Pick

What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?

Steenwijk MD, Daams M, Pouwels PJW, Balk LJ, Tewarie PK, Killestein J, Uitdehaag B M, Geurts JJG, Barkhof F, Vrenken H

Radiology. 2014 Apr 23:132708. PMID: 24761837. Abstract

Papers: 18 Apr 2014 - 25 Apr 2014

Check out this week's papers from PubMed. If you are a member, please log in to recommend and comment on papers. If you are not a member, please register today and join the conversation.

Is the Month-of-Birth Effect on MS Risk a Statistical Fluke?

Since the late 1980s, a series of papers have reported that people born in late spring, especially in May, are at greater risk for MS. Two recent papers contend that these results are a statistical fluke.

Scores of papers published in the last quarter-century have reported that people with MS are more likely to...

Methods, People

Editors' Pick

Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.

Bergvall N, Lahoz R, Reynolds T, Korn JR

Curr Med Res Opin. 2014 May 2. PMID: 24754349. Abstract

Editors' Pick

Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis.

Nerrant E, Salsac C, Charif M, Ayrignac X, Carra-Dalliere C, Castelnovo G, Goulabchand R, Tisseyre J, Raoul C, Eliaou J-F, et al.

Mult Scler. 2014 Apr 22. PMID: 24756568. Abstract

Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

User Top Menu

Few MS Patients Fail to Receive Disease-Modifying Therapy

MS Research Roundup: April 30, 2014

Race to Erase MS Forum and Expo

Papers: 18 Apr 2014 - 25 Apr 2014

Is the Month-of-Birth Effect on MS Risk a Statistical Fluke?

Pages

MSDF Footer

Search form

Papers: 18 Apr 2014 - 25 Apr 2014

Pages